Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have
summarised the scientific advances and future needs in this field through the efforts of …

Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

Background and Purpose: The diverse causes of right-sided heart failure (RHF) include,
among others, primary cardiomyopathies with right ventricular (RV) involvement, RV …

The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic
diseases in neonates, infants, and older children and contributes to significant morbidity and …

Background Current therapies for pulmonary arterial hypertension have been adopted on
the basis of short-term trials with exercise capacity as the primary end point. We assessed …